Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer

被引：5
|
作者：
Liu, Yajing [1 ]
Martin-Trevino, Rachel [1 ]
Shang, Li [1 ]
Davis, April [1 ]
Wicha, Max [1 ]
Liu, Suling [2 ]
Burness, Monika [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-4226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4226
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [2] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [3] Treatment with Histone Deacetylase Inhibitors Creates 'BRCAness' and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin
    Bhalla, K. N.
    Rao, R.
    Sharma, P.
    Das Gupta, S.
    Chauhan, L.
    Stecklein, S.
    Fiskus, W.
    CANCER RESEARCH, 2012, 72
  • [4] The response of histone deacetylase inhibitors in triple negative breast cancer
    Alzoubi, Madlin
    Nguyen, Khoa
    Burks, Hope
    Hebert, Katherine
    Cheng, Thomas
    Matossian, Margarite
    Wright, Maryl
    Collins-Burow, Bridgette
    Burow, Matthew
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Targeting triple negative breast cancer with histone deacetylase inhibitors
    Fedele, Palma
    Orlando, Laura
    Cinieri, Saverio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1199 - 1206
  • [6] Judy Garber on PARP inhibitors for triple-negative breast cancer
    Garber, Judy
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 814 - +
  • [7] New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
    Han, Ye
    Yu, Xiaopeng
    Li, Shuqiang
    Tian, Ye
    Liu, Caigang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer
    Li, Wenlong
    Yang, Hongmei
    Li, Xiaoli
    Han, Lou
    Xu, Ning
    Shi, Aiping
    ONCOLOGY REPORTS, 2019, 41 (01) : 437 - 446
  • [9] Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4
    Gu, Zhangyuan
    Ye, Fugui
    Luo, Hong
    Li, Xiaoguang
    Gong, Yue
    Mao, Shiqi
    Jia, Xiaoqing
    Han, Xiangchen
    Han, Boyue
    Fu, Yun
    Cheng, Xiaolin
    Li, Jiejing
    Shao, Zhiming
    Wen, Peizhen
    Hu, Xin
    Zhuang, Zhigang
    JOURNAL OF BIOMEDICAL SCIENCE, 2025, 32 (01)
  • [10] Unexpected selectivity of histone deacetylase inhibitors in live MDA-MD-231 triple-negative breast cancer cells
    Aboukhatwa, Shaimaa M.
    Hanigan, Thomas W.
    Neerasa, Jayaprakash
    Taha, Taha Y.
    Brown, Nathan D.
    El-Bastawissy, Eman E.
    Elkersh, Mohamed A.
    El-Moselhy, Tarek F.
    Frasor, Jonna
    Petukhov, Pavel A.
    CANCER RESEARCH, 2018, 78 (13)
12345